COVID-19 Integrates Into CROI

Article

The Conference on Retroviruses and Opportunistic Infections (CROI) begins today and SARS-CoV-2 has developed into a sustained topic at this annual conference.

The annual CROI conference is taking place in Seattle beginning today and running through Wednesday. With this conference, HIV has long been the cornerstone topic, and will continue to do so with a large variety of posters, abstracts, and presentations on the subject.

However, nearly 3 years since the pandemic began, COVID-19 has taken a foothold at CROI and research and data continue to be presented on the virus. The significant focus on the virus and interesting new findings on SARS-CoV-2 could pave the way to help clinicians better understand it and develop treatment strategies for optimal outcomes.

“It is really great to see how the COVID-related presentations have naturally integrated themselves into all the various categories,” Michael Peluso, MD, assistant professor, School of Medicine, UCSF said.

Aside from clinicians wanting to prevent severe acute COVID-19 infection, another area of concern related to the virus is Post-Acute Sequelae of SARS-CoV-2 (PASC) or otherwise known as Long COVID. Peluso will be speaking at CROI on this topic. His presentation, “What We Know Now About Long COVID Syndromes,” will be part of a symposium titled COVID-19: Where Are We Now? on Tuesday from 4:00 PM - 5:30 PM PT.

Long COVID continues to be a growing concern within health care and remain enigmatic in its nature, how it presents, and the best treatment strategies.

Contagion spoke with Peluso on his topic, and will present the interview after the embargo lifts later this week.

In this first interview segment, Peluso talks about what he is looking forward to at CROI.

Keep an eye out for our CROI coverage over the coming days as we will be onsite at the conference bringing you data and research on the latest topics as well as interviews with presenters, clinicians, and stakeholders.



Recent Videos
© 2024 MJH Life Sciences

All rights reserved.